Exact Sciences Corporation (NASDAQ:EXAS) is set to post its quarterly earnings results before the market opens on Tuesday, October 24th. Analysts expect Exact Sciences Corporation to post earnings of ($0.31) per share for the quarter.

Exact Sciences Corporation (NASDAQ:EXAS) last posted its earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.10. The company had revenue of $57.65 million for the quarter, compared to analyst estimates of $47.73 million. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. On average, analysts expect Exact Sciences Corporation to post $-1.19 EPS for the current fiscal year and $-0.8 EPS for the next fiscal year.

Shares of Exact Sciences Corporation (NASDAQ:EXAS) opened at 47.20 on Tuesday. The firm has a 50-day moving average of $44.75 and a 200 day moving average of $36.31. The firm’s market capitalization is $5.62 billion. Exact Sciences Corporation has a 12-month low of $13.05 and a 12-month high of $50.65.

A number of research firms recently issued reports on EXAS. Leerink Swann reiterated an “outperform” rating and set a $50.00 target price (up previously from $45.00) on shares of Exact Sciences Corporation in a research report on Thursday, September 21st. Vetr downgraded shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $36.37 target price on the stock. in a research report on Thursday, July 6th. Canaccord Genuity reiterated a “buy” rating and set a $60.00 target price (up previously from $45.00) on shares of Exact Sciences Corporation in a research report on Tuesday, October 3rd. BidaskClub upgraded shares of Exact Sciences Corporation from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 25th. Finally, BTIG Research reiterated a “buy” rating and set a $45.00 target price (up previously from $35.00) on shares of Exact Sciences Corporation in a research report on Monday, July 17th. Five analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $43.71.

In other news, CFO Jeffrey Thomas Elliott sold 5,846 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $39.41, for a total value of $230,390.86. Following the completion of the sale, the chief financial officer now owns 19,861 shares in the company, valued at approximately $782,722.01. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP D Scott Coward sold 29,115 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total transaction of $1,373,063.40. Following the completion of the sale, the senior vice president now owns 64,991 shares of the company’s stock, valued at approximately $3,064,975.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 237,444 shares of company stock worth $10,412,421. Corporate insiders own 4.00% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Exact Sciences Corporation (EXAS) Set to Announce Earnings on Tuesday” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/17/exact-sciences-corporation-exas-set-to-announce-earnings-on-tuesday.html.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Earnings History for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.